ONCOLOGY UPDATE

Experts from the Dr Rosell Oncology Institute co-authors of research presented at the Annual Congress of the American Society of Clinical Oncology (ASCO) 2014

03/06/2014

Barcelona, June 2014. Expert investigators from the Dr Rosell Oncology Institute are co-authors of results presented at the 2014 annual meeting of the American Society of Clinical Oncology (ASCO). Results presented include analyses of predictive biomarkers and novel mechanisms of resistance to targeted therapies, as well as the results of clinical trials and whole exome and transcriptome sequencing in collaboration with the US Cancer Therapeutics Innovation Group (GTIC). Results of the studies were presented during the congress in the form of posters.



 



Karachaliou et al.

Effect of BIM and mTOR expression on clinical outcome to erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients (p).

Abstract # 8072, Poster



Giannikopoulos et al.

Integrated genomic analysis reveals broad remodeling of EGFR targeted therapy resistant lung cancers.

Abstract # 8083, Poster



Garcia-Campelo et al.

PHASE IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small-cell lung cancer (NSCLC). (NCT=1513174/GECP-GOAL).

Abstract # 8079, Poster



Massuti et al.

Open, phase II randomized trial of gefitinib alone vs olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations. spanish lung cancer group trial (NCT=1513174/GECP-GOAL).

Abstract # TPS8127 Poster 



Gettinger et al.

Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).

Abstract # 8047 Poster


return